Free Trial

Zai Lab (ZLAB) Stock Forecast & Price Target

$18.86
-0.01 (-0.05%)
(As of 07/26/2024 ET)

Zai Lab - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 5 Wall Street analysts who have issued ratings for Zai Lab in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for ZLAB.

Consensus Price Target

$58.97
212.66% Upside
High Forecast$73.34
Average Forecast$58.97
Low Forecast$38.00

According to the 5 analysts' twelve-month price targets for Zai Lab, the average price target is $58.97. The highest price target for ZLAB is $73.34, while the lowest price target for ZLAB is $38.00. The average price target represents a forecasted upside of 212.66% from the current price of $18.86.

TypeCurrent Forecast
7/27/23 to 7/26/24
1 Month Ago
6/27/23 to 6/26/24
3 Months Ago
4/28/23 to 4/27/24
1 Year Ago
7/27/22 to 7/27/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$58.97$64.57$64.22$86.38
Forecasted Upside212.66% Upside155.12% Upside150.68% Upside168.29% Upside
Get Zai Lab Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZLAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zai Lab Stock vs. The Competition

TypeZai LabMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside212.66% Upside3,123.46% Upside9.18% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/12/2024JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$43.00 ➝ $38.00+108.11%
7/1/2024Cantor Fitzgerald
3 of 5 stars
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
2/29/2024Citigroup
3 of 5 stars
 Lower TargetBuy ➝ Buy$123.00 ➝ $66.00+206.26%
12/14/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$47.50+58.76%
10/26/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$82.47 ➝ $73.34+212.75%
6/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$75.00 ➝ $62.50+119.92%
10/20/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$83.00+193.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:51 AM ET.

ZLAB Forecast - Frequently Asked Questions

What is Zai Lab's forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Zai Lab is $58.97, with a high forecast of $73.34 and a low forecast of $38.00.

Should I buy or sell Zai Lab stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.

Does Zai Lab's stock price have much upside?

According to analysts, Zai Lab's stock has a predicted upside of 153.30% based on their 12-month stock forecasts.

What analysts cover Zai Lab?

Zai Lab has been rated by research analysts at Cantor Fitzgerald, and JPMorgan Chase & Co. in the past 90 days.

Do Wall Street analysts like Zai Lab more than its competitors?

Analysts like Zai Lab more than other "medical" companies. The consensus rating for Zai Lab is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZLAB compares to other companies.


This page (NASDAQ:ZLAB) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners